Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report.
Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report.
复制标题
DOI：
10.3390/idr13020042
复制
发表时间：
2021-05-17
影响因子：
3.2
通讯作者：
Irwinda R
中科院分区：
文献类型：
--
作者：
Saroyo YB;Rumondang A;Febriana IS;Harzif AK;Irwinda R
简介：导致2019新型冠状病毒病（COVID-19）的严重急性呼吸系统综合征冠状病毒2型（SARS-CoV-2）感染已成为全球主要健康问题，并自2020年3月起被WHO宣布为大流行病。一个构成挑战的特殊人群是感染COVID-19的孕妇。目前还没有太多关于COVID-19在怀孕期间的研究。在这项研究中，我们介绍了五个系列病例，Remdesivir治疗COVID-19的孕妇中度至重度症状。病例说明：我们简要描述了五个连续病例在住院期间接受Remdesivir治疗。4例剖宫产分娩，1例于孕37周经阴道分娩。所有病例均显示住院时间缩短，临床症状迅速改善，未观察到母亲、胎儿和新生儿不良事件。讨论：瑞德西韦是一种RNA聚合酶抑制剂，已用于COVID-19治疗，已知可缩短非孕妇的恢复时间。一些研究表明Remdesivir对孕妇没有不良影响。根据埃博拉疫情期间的随机对照试验（RCT），Remdesivir可安全用于孕妇。所有病例均显示住院时间缩短，临床结局更好，无母体、胎儿或新生儿不良事件。结论：Remdesivir方案用于患有中度至重度COVID-19症状的孕妇，临床改善效果更好，恢复期更短，住院期间无不良反应。需要进一步的研究和RCT来评估Remdesivir在孕妇中的生物安全性和效果。
Introduction: Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) infection that causes novel Coronavirus Disease 2019 (COVID-19) has become a major health problem worldwide and been declared a pandemic since March 2020 by WHO. One special population that poses a challenge is pregnant women with COVID-19. There have not been many studies related to COVID-19 in pregnancy. In this study, we present five serial cases of Remdesivir treatment for COVID-19 in pregnant women with moderate to severe symptoms. Case Illustration: We briefly describe five serial cases being treated with Remdesivir therapy during hospitalization. Four cases were delivered by cesarean section, and one was delivered vaginally in gestation week 37. All cases showed a shortened duration of hospitalization, rapid improvement in clinical symptoms, and no adverse events were observed in mothers, fetuses, and neonates. Discussion: Remdesivir, an inhibitor RNA Polymerase, has been used in COVID-19 treatment and is known to shorten recovery time in nonpregnant women. Some studies have shown no adverse effects on Remdesivir for pregnant women. Based on randomized control trial (RCT) during the Ebola epidemic, Remdesivir was safe to use for pregnant women. All cases showed reduced hospitalization time and better clinical outcomes without maternal, fetal, or neonatal adverse events. Conclusion: Remdesivir protocol for pregnant women with moderate to severe symptoms of COVID-19 has resulted in better clinical improvement with a shorter recovery period and no adverse effects during the hospitalization period. Further studies and RCT are warranted to evaluate the biosafety and effects of Remdesivir in pregnant women.
影响因子：
15.1
作者：
Odayar J;Myer L;Malaba TR
通讯作者：
Malaba TR